Recordati SpAMIL:REC +0.88%96 Market Cap is €10,489 Mil as of Jun. 25, 2026. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.64 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Recordati SpA ranks better than 95.7% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Recordati SpA's share price for the quarter that ended in Mar. 2026 was €49.04. Recordati SpA's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 203 Mil. Therefore, Recordati SpA's market cap for the quarter that ended in Mar. 2026 was €9,976 Mil.
Recordati SpA's quarterly market cap
declined
from Sep. 2025 (€10,576 Mil) to Dec. 2025 (€9,919 Mil) but then
increased
from Dec. 2025 (€9,919 Mil) to Mar. 2026 (€9,976 Mil).
Recordati SpA's annual market cap
increased
from Dec. 2023 (€10,059 Mil) to Dec. 2024 (€10,439 Mil) but then
declined
from Dec. 2024 (€10,439 Mil) to Dec. 2025 (€9,919 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Recordati SpA's Enterprise Value for Today is €12,475 Mil.
Recordati SpA (MIL:REC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Recordati SpA Market Cap Related Terms
Recordati SpA Market Cap Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Recordati SpA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Market Cap distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Recordati SpA's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a Market Cap of €10,489 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Recordati SpA and its competitors. According to the industry distribution chart, Recordati SpA ranks #44 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Recordati SpA's Market Cap too high?
Recordati SpA's current Market Cap is €10,489 Mil. Based on the distribution chart, Recordati SpA ranks #44 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #44 out of 1023 companies for Market Cap. This places Recordati SpA in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 207.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 207.38, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median Market Cap is 207.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Market Cap is €10,489 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.64, compared to a current price of €51.55 — trading 15% below its estimated fair value. The current Market Cap is €10,489 Mil. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Market Cap is €10,489 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.55 is trading 15% below its estimated GF Value™ of €60.64.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
Market Cap: €10,489 Mil
GF Value™: €60.64 vs. price of €51.55 (15% below fair value)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
